We have examined whether propofol activates complement. In the first study, blood was mixed with saline, propofol or the lipid solvent for propofol, and the activated complement 3 (C3a) and 4 (C4a) concentrations in the supernatant were assayed. In the second study, blood and propofol were mixed with various levels of nafamostat mesilate (anti-complement agent) up to 0.3 mmol/l and the C3a was assayed. In the third study, the time course of plasma C3a concentration in patients during propofol anaesthesia was examined. The results showed that the lipid solvent activated complement and produced similar levels of C3a to propofol, probably via both the classical and alternative pathways. This activation was not inhibited by any of the nafamostat concentrations used. There was no significant change in plasma C3a concentration during propofol anaesthesia. These results suggest that C3a is generated by the lipid solvent, but its accumulation during propofol anaesthesia is minimal.
Some reports 1,2 have described pulmonary oedema appearing during propofol anaesthesia, whilst other reports [3] [4] [5] have suggested that propofol does not aggravate pulmonary oedema. Thus, whether propofol causes this complication remains controversial. Although there are many causes of pulmonary oedema, we have speculated on two possible mechanisms for propofol-induced pulmonary oedema; one is that the lipid solvent for propofol forms lipid droplets in blood, resulting in fat embolism in the peripheral lung vessels. The other is that propofol activates complement after contact with the blood. Regarding the former speculation, we have not observed the formation of lipid droplets during propofol anaesthesia, suggesting that these doses do not cause pulmonary oedema 6 . Regarding the latter speculation, there is one report 7 suggesting that complement is activated by propofol. The evidence that complement activation is a potential cause of pulmonary oedema has been widely documented [8] [9] [10] , and clinically, organ dysfunction after cardiopulmonary bypass has been considered to be a result of complement activation by use of the artificial lung 11 . This study was designed to examine whether propofol activates complement in vitro and in vivo.
MATERIALS AND METHODS
This study was approved by the Institutional Committee, and all patients, who were classified at ASA physical status 1, gave informed consent. The patient received a 20-gauge intravenous catheter in the forearm into which acetate Ringer's solution was infused, and was premedicated with 0.06 mg/kg atropine and 1 mg butorphanol intramuscularly 30 minutes before entering the operating room.
Complement Activation by Propofol and Its Solvent
Ten adult female patients who underwent gynaecological laparoscopic examination were enrolled. Three plastic syringes, each containing 1 ml of saline, 1% propofol or 10% lipid solvent (Intralipid, Kabi Pharmacia AB, Stockholm, Sweden), were prepared at room temperature. Anaesthesia was induced with 5 mg/kg thiamylal, followed by inhalation of 1.5% isoflurane and 33% O 2 /N 2 O by manual ventilation using a face mask. After induction of anaesthesia, an 18-gauge intravenous catheter was inserted into the long saphenous vein at the ankle. Subsequently, 2 ml venous blood was aspirated from this catheter over five seconds during the application of a proximal venous tourniquet using the prepared syringes in turn. Each sample was mildly shaken for 20 seconds and immediately mixed with edetic acid and nafamostat mesilate, followed by centrifugation at 4°C. The supernatant was used for activated complement 3 (C3a) and 4 (C4a) measurement. After collection of these samples, 0.1 mg/kg vecuronium was administered, a laryngeal mask airway was inserted and surgery started.
Inhibitory Effect of Nafamostat Mesilate on Complement Activation
Eight adult female patients who underwent gynaecological laparoscopic examination were enrolled. Nafamostat mesilate (Torii Pharmaceutical, Tokyo, Japan), molecular weight 539.58, was prepared by diluting a 10 mg vial with 1 ml of 5% glucose. This solution was diluted 1:10 in turn with 5% glucose three times, to obtain 10, 1, 0.1 and 0.01 mg/ml nafamostat solutions. Five plastic syringes, containing 1 ml of 1% propofol mixed with either 0.05 ml of 5% glucose (non-nafamostat), 0.05 ml of 0.01 mg/ml nafamostat solution (0.001 mmol/l nafamostat), 0.05 ml of 0.1 mg/ml nafamostat solution (0.01 mmol/l nafamostat), 0.05 ml of 1 mg/ml nafamostat solution (0.1 mmol/l nafamostat), or 0.05 ml of 10 mg/ml nafamostat solution (1 mmol/l nafamostat), were prepared at room temperature. Anaesthesia was induced with 5 mg/kg thiamylal, followed by inhalation of 1.5% isoflurane and 33% O 2 /N 2 O by manual ventilation using an oral mask. After induction of anaesthesia, an 18-gauge intravenous catheter was inserted into the long saphenous vein at the ankle. Subsequently, 2 ml of venous blood was aspirated from this catheter over five seconds into the prepared syringes in turn during proximal venous tourniquet. Each sample was gently shaken for 20 seconds and immediately mixed with edetic acid and nafamostat mesilate, followed by centrifugation at 4°C. The supernatant was used for C3a measurement. After collection of these samples, anaesthesia and surgery were carried out in the same way as in the first study.
Time Course of Plasma C3a Concentration during Propofol Anaesthesia
Ten adult female patients who were to have an abdominal total hysterectomy for benign disease were enrolled. Fifteen minutes after injection of 12 ml 2% mepivacaine through an epidural catheter inserted via the first lumbar interspace, the spread of the block was assessed with an alcohol swab and 2 ml arterial blood was collected from the femoral artery using a plastic syringe. Subsequently, anaesthesia was induced with 2.5 mg/kg of 1% propofol at a flow rate of 200 mg/minute and the laryngeal mask airway was inserted, followed by inhalation of 40% O 2 with mechanical ventilation. Anaesthesia was maintained with propofol at 10 mg/kg/hour for 10 minutes, 8 mg/kg/hour for 10 minutes and 6 mg/kg/hour thereafter. Intermittent epidural injection of 6 to 8 ml of 2% mepivacaine was administered at 45-minute intervals. Surgery started several minutes after the second epidural injection. During anaesthesia and surgery, 2 ml arterial blood was collected from the femoral artery or the radial artery, 3, 60 and 120 minutes after the administration of propofol. Each blood sample was immediately mixed with edetic acid and nafamostat mesilate, followed by centrifugation at 4°C. The plasma obtained was used for C3a measurement.
Assay of Activated Complement and Statistical Analysis
The C3a and C4a concentrations were assayed by radioimmunoassay (Human Complement C3a des Arg [ 125 I] and C4a des Arg [ 125 I] Assay Systems, Amersham International, Bucks, U.K.). C3a and C4a are rapidly catabolized by plasma carboxypeptidase into C3a des Arg and C4a des Arg 12 , respectively, and these assay kits detect both activated complement and its des Arg form.
Statistical analysis for comparison of C3a or C4a concentrations between the syringes was made using one-way analysis of variance with Fisher's protected least significant difference. For the change in plasma C3a concentration during propofol anaesthesia, repeated measure one-way analysis of variance was performed. Data are presented as mean ±SD. P<0.05 was considered significant. (Figure 1) The age, weight and height of the patients examined were 36±4 y (range 32-45 y), 52±7 kg and 156±5 cm respectively.
RESULTS

Complement Activation by Propofol and Its Solvent
The C3a concentration in the saline, propofol and lipid solvent syringes was 120±78, 274±148 and 245±161 ng/ml, respectively. There was a statistically significant difference between these values (P=0.037). The concentrations in the propofol and lipid solvent syringes were significantly higher than that in the saline syringe.
The C4a concentration in the saline, propofol and lipid solvent syringes was 149±181, 382±355 and 385 ±390 ng/ml, respectively. There was no significant difference between these values (P=0.189). (Figure 2) The age, weight and height of the patients examined were 36±4 y (range 33-45 y), 51±5 kg and 155±5 cm respectively.
Inhibitory Effect of Nafamostat Mesilate on Complement Activation
The C3a concentration in the non-nafamostat, 0.001 mmol/l nafamostat, 0.01 mmol/l nafamostat, 0.1 mmol/l nafamostat and 1 mmol/l nafamostat syringes was 256±151, 259±134, 237±123, 219±113 and 205 ±125 ng/ml, respectively. There was no statistically significant difference between these values (P= 0.1545). (Figure 3) The age, weight and height of the patients examined were 48±9 y (range 40-69 y), 51±5 kg and 155±5 cm. The upper anaesthetized thoracic dermatome level was 5.3±0.9 (median 6, range 4-6), and estimated blood loss during surgery was 157±41 ml (range 70-230 ml).
Time Course of Plasma C3a Concentration during Propofol Anaesthesia
The plasma C3a concentration before propofol induction and 3, 60 and 120 minutes thereafter was 135±60, 146±50, 149±57 and 152±68 ng/ml, respectively. There was no statistically significant change (P=0.637).
DISCUSSION
C3a and C4a are released by activation of complement 3 and 4 and are subsequently broken down by plasma carboxypeptidase to form C3a and C4a des Arg, which are physiologically inactive 12 . Since the assay kits used in this study detect both substances, an increased concentration of C3a or C4a indicates the activation of complement 3 or 4. There are two routes of complement activation; the classical pathway and the alternative pathway. When C3a is produced in the classical pathway, C4a is produced similarly 11 . The first study revealed that mixing blood with propofol increases the C3a concentration about two-fold compared with mixing blood with saline. Since this increase was observed similarly in a mixture of blood and lipid solvent, it seems that complement activation by propofol can be attributed to the lipid solvent. The C4a data measured at the same time was not identical to the C3a data, but the tendency was similar. We considered therefore, that complement activation by propofol is dependent on both the classical and alternative pathways.
Nafamostat mesilate is widely known as the strongest anti-complement agent out of a variety of serine protease inhibitors [13] [14] [15] . This drug is used clinically in Japan for treating patients with disseminated intravenous coagulation and acute pancreatitis, and as an anticoagulant during various extracorporeal circulation procedures 16 . The second study was designed to examine what dose of nafamostat inhibited complement activation by propofol. Since propofol containing nafamostat was mixed with blood in a 1:2 ratio, the actual concentrations of nafamostat tested were approximately 0.0003, 0.003, 0.03 and 0.3 mmol/l. However, none of these concentrations inhibited complement activation. A concentration of 0.3 mmol/l nafamostat is the highest clinical level 14 . Thus, we concluded that clinical doses of nafamostat cannot inhibit complement activation by propofol.
Whether C3a produced by propofol increases its plasma concentration in patients during propofol anaesthesia is clinically significant. Consequently, we examined the change in arterial plasma C3a concentration during propofol anaesthesia for two hours at a relatively high clinical dose. All patients examined were classified as ASA physical status 1 and to receive a gynaecological lower abdominal surgery with minimum blood loss, in which an early endocrine response via neuronal pathways is completely inhibited by epidural anaesthesia to the upper thoracic dermatome level 17, 18 . Since complement activation occurs during an early phase of sepsis, trauma and pancreatitis 19 , the early endocrine response during surgery may affect plasma complement concentrations. The anaesthetized levels obtained in the present patients reached the 4th to 6th thoracic level which was sufficient to inhibit the early endocrine response. In these conditions, any change in plasma C3a concentrations would be attributable to extrinsic C3a infusion. The results obtained, however, showed no significant changes in plasma C3a concentrations. This finding shows that propofol-generated C3a does not increase arterial plasma levels, probably due to the low generation and infusion of C3a. Although brief propofol anaesthesia would not affect patients' complement levels as discussed above, the levels might be affected by C3a accumulation during prolonged propofol anaesthesia or prolonged propofol infusion for sedation in critically ill patients. In cases where propofol anaesthesia-associated complications are noticed, the evidence obtained in this study shows that complement activation by propofol, possibly resulting in increased concentrations of C3a, should be considered. It is possible that propofol-associated pulmonary oedema can be attributed to complement activation by propofol.
In conclusion, the studies reported here have demonstrated that the lipid solvent for propofol activates complement and produces C3a, probably via both the classical and alternative pathways. Although a systemic accumulation of C3a was not noticed during standard propofol anaesthesia for healthy patients, this finding should be considered whenever propofol is infused for prolonged anaesthesia or prolonged sedation, particularly in critically ill patients.
